SecBot SecBot
SECBOTREPLAY Home › Report › IVVD

IVVD · Invivyd reported strong financial and clinical progress, with Q4 2025…

Invivyd, Inc. · 8-K filed Mar 5, 2026 at 07:12 ET

At the news

BULLISHIMPACT 8/10

8-K filed Mar 5, 2026 at 07:12 ET

Invivyd reported strong financial and clinical progress, with Q4 2025 PEMGARDA net product revenue of $17.2 million (25% YoY growth) and a year-end cash position of $226.7 million after raising over $200 million in 2H 2025. The company's pivotal DECLARATION Phase 3 trial for its COVID-19 antibody VYD2311 is fully enrolled with top-line data expected mid-2026, and the FDA granted Fast Track designation for the candidate.

  • Achieved Q4 2025 PEMGARDA net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter
  • 2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025
  • Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026
  • Fast Track designation for VYD2311 granted by FDA in December 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access